Cargando…

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy

Detalles Bibliográficos
Autores principales:	Finkel, Richard S., Schara-Schmidt, Ulrike, Hagenacker, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399626/ https://www.ncbi.nlm.nih.gov/pubmed/32849232 http://dx.doi.org/10.3389/fneur.2020.00783

Ejemplares similares

Spinal astrocyte dysfunction drives motor neuron loss in late-onset spinal muscular atrophy
por: Schmitt, Linda-Isabell, et al.
Publicado: (2023)

Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy
por: Kizina, Kathrin, et al.
Publicado: (2019)

Assessment of Health-Related Quality of Life in Adult Spinal Muscular Atrophy Under Nusinersen Treatment—A Pilot Study
por: Thimm, Andreas, et al.
Publicado: (2022)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
por: Savini, Giovanni, et al.
Publicado: (2021)

Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy
por: Millere, Elina, et al.
Publicado: (2021)

Analysis of Free Circulating Messenger Ribonucleic Acids in Serum Samples from Late-Onset Spinal Muscular Atrophy Patients Using nCounter NanoString Technology
por: Leo, Markus, et al.
Publicado: (2023)

Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
por: Kotulska, Katarzyna, et al.
Publicado: (2021)

25 years of the SMN genes: the Copernican revolution of spinal muscular atrophy
por: Tiziano, Francesco Danilo, et al.
Publicado: (2020)

Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
por: Kariyawasam, Didu S. T., et al.
Publicado: (2019)

Expression of Human Endogenous Retrovirus-K in Spinal and Bulbar Muscular Atrophy
por: Rex, Cody, et al.
Publicado: (2019)

Editorial: Advances in spinal muscular atrophy
por: Sun, Jianli
Publicado: (2023)

Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
por: Kizina, K., et al.
Publicado: (2020)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type I-III
por: Kölbel, Heike, et al.
Publicado: (2017)

Correlation Between Maximal Tongue Pressure and Swallowing Function in Spinal and Bulbar Muscular Atrophy
por: Gwak, Dae-Won, et al.
Publicado: (2021)

Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy
por: Järvilehto, Julius, et al.
Publicado: (2022)

Real-World Data on Access to Standards of Care for People With Spinal Muscular Atrophy in the UK
por: Muni-Lofra, Robert, et al.
Publicado: (2022)

Sociodemographic and clinical characteristics and access to health care in patients with spinal muscular atrophy in Argentina
por: Vazquez, Gabriel Adolfo, et al.
Publicado: (2023)

Correction: Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type I-III
por: Kölbel, Heike, et al.
Publicado: (2017)

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020)

Spinal Muscular Atrophy and Communicating Hydrocephalus: A Novel or a Well-Established Rare Association?
por: Alkhars, Fatimah Z, et al.
Publicado: (2020)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Addressing the implementation gap in advanced therapeutics for spinal muscular atrophy in the era of newborn screening programs
por: Leon-Astudillo, Carmen, et al.
Publicado: (2022)

Lowered oxidative capacity in spinal muscular atrophy, Jokela type; comparison with mitochondrial muscle disease
por: Ratia, Nadja, et al.
Publicado: (2023)

Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era
por: Giorgia, Querin, et al.
Publicado: (2023)

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
por: Osmanovic, Alma, et al.
Publicado: (2021)

Objective measurement of oral function in adults with spinal muscular atrophy
por: Kruse, T., et al.
Publicado: (2023)

Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients
por: Yeo, Crystal J. J., et al.
Publicado: (2022)

Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives
por: Farrar, Michelle A, et al.
Publicado: (2018)

Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis
por: Darbà, Josep, et al.
Publicado: (2019)

Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment
por: Nigro, Elisa, et al.
Publicado: (2023)

Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy
por: Tan, Hiangkiat, et al.
Publicado: (2019)

Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy
por: Tan, Hiangkiat, et al.
Publicado: (2019)

Biomarkers in 5q-associated spinal muscular atrophy—a narrative review
por: Lapp, H. S., et al.
Publicado: (2023)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018)

Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen
por: Yae, Yukako, et al.
Publicado: (2022)

Cognitive impairment in Chinese adult patients with type III spinal muscular atrophy without disease-modifying treatment
por: Hu, Ying, et al.
Publicado: (2023)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

Intrathecal Access Through Suboccipital Port in Patients With Spinal Muscular Atrophy and Complex Spines: Case Series and Technical Note
por: Tran, Diem Kieu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q4i2p17nkovtf3uqlc5ol35pur